Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Planchard Tags: EDITORIALS Source Type: research

Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Wirth Tags: EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Theurich, Schlaak, Steguweit, Heukamp, Wennhold, Kurschat, Rabenhorst, Hartmann, Schlosser, Shimabukuro-Vornhagen, Holtick, Hallek, Stadler, von Bergwelt-Baildon Tags: Biologic Therapy, Biology & Immunology, Translational Oncology, Non-Melanoma Skin Cancer, Hematologic, Other DIAGNOSIS IN ONCOLOGY Source Type: research

Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Ricci, Martini, Cenci, Antinori, Cassano, Larocca Tags: Epidemiology, Chemotherapy, Translational Oncology, Chemotherapy, Translational Oncology, Rhabdo & Other Soft Tissue Sarcomas:, Gastrointestinal, Sarcomas, Chromosomal Abnormalities, Gene Expression and Profiling DIAGNOSIS IN ONCOLOGY Source Type: research

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - April 12, 2016 Category: Cancer & Oncology Authors: Smyth, Yagita, McArthur Tags: Combined Modality, Translational Oncology, Melanoma, Immunology/Immunobiology DIAGNOSIS IN ONCOLOGY Source Type: research

ERRATA [Errata]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Tags: Errata Source Type: research

Reply to S. Alanee et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Fung, Fossa, Milano, Sahasrabudhe, Peterson, Travis Tags: CORRESPONDENCE Source Type: research

Cardiovascular Disease Mortality After Diagnosis With Extragonadal Germ Cell Tumors [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Alanee, Dynda Tags: CORRESPONDENCE Source Type: research

Reply to M.C. Scholz et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: DAmico Tags: CORRESPONDENCE Source Type: research

Query About the Frequency of Biopsy Complications [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Scholz, Lam, Turner Tags: CORRESPONDENCE Source Type: research

Reply to T.J. Kruser et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Chinot, Taphoorn, Bais, Bourgon, Phillips, Abrey, Wick, Mason, Henriksson, Saran, Nishikawa, Cloughesy Tags: CORRESPONDENCE Source Type: research

Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma--An Easy Question Turned Difficult: Treat the Scan or the Patient? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Kruser, Mehta, Kozak Tags: CORRESPONDENCE Source Type: research

"It Is What It Is" [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Oosterwijk Tags: Emotions of the oncologist, Ethics and legal issues, Patient communication, All Art of Oncology Articles Source Type: research

Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events [STATISTICS IN ONCOLOGY]
Purpose To compare a novel generalized competing event (GCE) model versus the standard Cox proportional hazards regression model for stratifying elderly patients with cancer who are at risk for competing events. Methods We identified 84,319 patients with nonmetastatic prostate, head and neck, and breast cancers from the SEER-Medicare database. Using demographic, tumor, and clinical characteristics, we trained risk scores on the basis of GCE versus Cox models for cancer-specific mortality and all-cause mortality. In test sets, we examined the predictive ability of the risk scores on the different causes of death, including...
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Carmona, Zakeri, Green, Hwang, Gulaya, Xu, Verma, Williamson, Triplett, Rose, Shen, Vaida, Murphy, Mell Tags: Prognostic Studies, Statistics in Oncology Source Type: research

Mantle Cell Lymphoma [REVIEW ARTICLE]
Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poor prognosis. Large gains were made in the first decade of the new century when clinical trials established the importance of high-dose therapy and autologous stem-cell rescue and high-dose cytarabine in younger patients and the benefits of maintenance rituximab and bendamustine in older patients. In particular, greater depth of understanding of the molecular pathophysiology of MCL has resulted in an explosion of specifically targeted new efficacious agents. In particular, agents recently approved by the Food and Dru...
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Cheah, Seymour, Wang Tags: Epidemiology, Diagnosis & Staging, Chemotherapy, Biologic Therapy, Biology & Immunology, Translational Oncology REVIEW ARTICLE Source Type: research

Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer [Treatment-Related Complications]
Conclusion SNHL is a late effect of RT that likely worsens over time. Long-term audiologic follow-up for a minimum of 10 years post-RT is recommended. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Bass, Hua, Huang, Onar-Thomas, Ness, Jones, White, Bhagat, Chang, Merchant Tags: Long Term Survival & Late Effects, CNS Tumors, Radiation Oncology Treatment-Related Complications Source Type: research

Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol [Pediatric Oncology]
Conclusion Two years after chemotherapy-only treatment, neurocognitive function is largely age appropriate. Nonetheless, survivors remain at elevated risk for attention problems that impact real-world functioning. Attention problems at the end of therapy predicted decreased academics 2 years later, suggesting an amplified functional impact of discrete neurocognitive difficulties. Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Jacola, Krull, Pui, Pei, Cheng, Reddick, Conklin Tags: Behavioral and Lifestyle Risk Factors, Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, Outcomes Research, Quality of Life Pediatric Oncology Source Type: research

Burden of Geriatric Events Among Older Adults Undergoing Major Cancer Surgery [Health Services and Outcomes]
Purpose Most malignancies are diagnosed in older adults who are potentially susceptible to aging-related health conditions; however, the manifestation of geriatric syndromes during surgical cancer treatment is not well quantified. Accordingly, we sought to assess the prevalence and ramifications of geriatric events during major surgery for cancer. Patients and Methods Using Nationwide Inpatient Sample data from 2009 to 2011, we examined hospital admissions for major cancer surgery among elderly patients (ie, age ≥ 65 years) and a referent group age 55 to 64 years. From these observations, we identified geriatric events...
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Tan, Saliba, Kwan, Moore, Litwin Tags: Population and observational studies (SEER, WHI observational, etc.), Geriatric Oncology, Quality of Care Health Services and Outcomes Source Type: research

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer [Thoracic Oncology]
The objective of this study was to assess the effect of TLI in lung cancer. Patients and Methods A discovery set (one trial, n = 824) and a validation set (three trials, n = 984) that evaluated the benefit of platinum-based adjuvant chemotherapy in non–small-cell lung cancer were used as part of the LACE-Bio (Lung Adjuvant Cisplatin Evaluation Biomarker) study. TLI was defined as intense versus nonintense. The main end point was overall survival (OS); secondary end points were disease-free survival (DFS) and specific DFS (SDFS). Hazard ratios (HRs) and 95% CIs associated with TLI were estimated through a multivariab...
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Brambilla, Le Teuff, Marguet, Lantuejoul, Dunant, Graziano, Pirker, Douillard, Le Chevalier, Filipits, Rosell, Kratzke, Popper, Soria, Shepherd, Seymour, Tsao Tags: Pathology, Immunology/Immunobiology Thoracic Oncology Source Type: research

Depressive Symptoms in Patients Scheduled for Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery: Prospective Associations With Morbidity and Mortality [Palliative and Supportive Care]
Conclusion Patients with clinically significant levels of preoperative depressive symptoms are at risk for poor clinical outcomes after HIPEC + CS, including greater risk of 30-day morbidity and readmission. Further research is warranted to determine biobehavioral mechanisms and examine whether effective interventions targeting preoperative depressive symptoms can reduce postoperative risk in this patient population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Low, Bovbjerg, Ahrendt, Alhelo, Choudry, Holtzman, Jones, Pingpank, Ramalingam, Zeh, Zureikat, Bartlett Tags: Supportive Care, Surgery, Quality of Life, Surgical Oncology Palliative and Supportive Care Source Type: research

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study [Breast Cancer]
Conclusion CHEK2*1100delC heterozygosity is associated with 15% to 82% increased risk for at least some cancers in addition to breast cancer. This information may be useful in clinical counseling of patients with this loss-of-function mutation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Naslund-Koch, Nordestgaard, Bojesen Tags: Epidemiology, Genetic epidemiology, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Epidemiology, Epidemiology, Epidemiology, Epidemiology & Prevention, Epidemiology, Epidemiology, Epidemiology, Epidemiology Breast Ca Source Type: research

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy [Breast Cancer]
Purpose An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for metastatic breast cancer. Methods Women with hemoglobin ≤ 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, were randomly assigned to EPO 40,000 IU subcutaneously once a week or best standard of care. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, time to tumor progression, overall response rate, RBC transfusions, and thrombotic vascular events. Results I...
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Leyland-Jones, Bondarenko, Nemsadze, Smirnov, Litvin, Kokhreidze, Abshilava, Janjalia, Li, Lakshmaiah, Samkharadze, Tarasova, Mohapatra, Sparyk, Polenkov, Vladimirov, Xiu, Zhu, Kimelblatt, Deprince, Safonov, Bowers, Vercammen Tags: Chemotherapy, Clinical Trials, Quality of Life Breast Cancer Source Type: research

Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study [Breast Cancer]
Purpose Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option for the management of ductal carcinoma in situ (DCIS). We sought to determine the survival benefit of RT after BCS on the basis of risk factors for local recurrence. Patients and Methods A retrospective longitudinal cohort study was performed to identify patients with DCIS diagnosed between 1988 and 2007 and treated with BCS by using SEER data. Patients were divided into the following two groups: BCS+RT (RT group) and BCS alone (non-RT group). We used a patient prognostic scoring model to stratify patients on the basis of risk o...
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Sagara, Freedman, Vaz-Luis, Mallory, Wong, Aydogan, DeSantis, Barry, Golshan Tags: Epidemiology, Radiation Breast Cancer Source Type: research

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database [Gastrointestinal Cancer]
Conclusion Early mortality was infrequent but more prevalent in patients with advanced age and a PS of ≥ 2, underscoring the need to carefully consider the risk-to-benefit ratio when making treatment decisions in these subgroups. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Cheung, Renfro, Kerr, de Gramont, Saltz, Grothey, Alberts, Andre, Guthrie, Labianca, Francini, Seitz, OCallaghan, Twelves, Van Cutsem, Haller, Yothers, Sargent Tags: Clinical Trials, Prognostic Studies, Epidemiology Gastrointestinal Cancer Source Type: research

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi [Rapid Communication]
Conclusion With these mature results, we confirm that patients with advanced Hodgkin lymphoma have similar OS results when treated with ABVD, BEACOPP, or CEC. However, with longer follow-up, we were not able to confirm the superiority of BEACOPP over ABVD in terms of PFS, mainly because of higher mortality rates resulting from second malignancies observed after treatment with BEACOPP and CEC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Merli, Luminari, Gobbi, Cascavilla, Mammi, Ilariucci, Stelitano, Musso, Baldini, Galimberti, Angrilli, Polimeno, Scalzulli, Ferrari, Marcheselli, Federico Tags: Chemotherapy, Combined Modality, Rapid Communications Source Type: research

Toward Minimizing Overtreatment and Undertreatment of Ductal Carcinoma In Situ in the United States [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Smith Tags: Radiation EDITORIALS Source Type: research

Big Data, Small Effects [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Hochster, Niedzwiecki Tags: Clinical Trials, Risk factors, Diagnosis & Staging, Combined Modality EDITORIALS Source Type: research

ABVD or BEACOPP for Advanced Hodgkin Lymphoma [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Engert Tags: EDITORIALS Source Type: research

Acknowledgment of Reviewers, 2015 [SPECIAL ARTICLE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Tags: SPECIAL ARTICLE Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Gasparotto, Rossi, Campagna, Scavina, Tiziano, Marzotto, Toffolatti, Vitelli, Amini, Dei Tos, Maestro Tags: Unknown Primary Site and Rare Cancers, Diagnosis & Staging, Rhabdo & Other Soft Tissue Sarcomas:, Sarcomas DIAGNOSIS IN ONCOLOGY Source Type: research

Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Harding, MacQuillan, Howman, de Boer, Adams, Mitchell, Jeffrey Tags: Chemotherapy, Biological Therapy DIAGNOSIS IN ONCOLOGY Source Type: research

Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 29, 2016 Category: Cancer & Oncology Authors: Rozati, Kempf, Ostheeren-Michaelis, Bode-Lesniewska, Zimmermann, Dummer, Cozzio Tags: Diagnosis & Staging DIAGNOSIS IN ONCOLOGY Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Brachytherapy: Where Has It Gone...Again? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Patel, Ragab, Demanes, Chen, Kamrava Tags: CORRESPONDENCE Source Type: research

Oncogastroenterology [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Grover, Lim, Blumberg, Syngal Tags: CORRESPONDENCE Source Type: research

Reply to W. Hryniuk et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Rock, Demark-Wahnefried, Byers, Colditz, Liu, Pakiz, Sedjo, Ganz Tags: CORRESPONDENCE Source Type: research

Reply to N. Osazuwa-Peters et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Ringash Tags: CORRESPONDENCE Source Type: research

Psychiatric Disorders Impeding Weight Loss in Obese Breast Cancer Survivors [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Hryniuk, Jenkins, Djuric Tags: CORRESPONDENCE Source Type: research

Suicide: A Major Threat to Head and Neck Cancer Survivorship [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Osazuwa-Peters, Adjei Boakye, Walker, Varvares Tags: CORRESPONDENCE Source Type: research

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods A literature search and prospectively defined study selection sought systematic reviews, meta-analyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline r...
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Harris, Ismaila, McShane, Andre, Collyar, Gonzalez-Angulo, Hammond, Kuderer, Liu, Mennel, Van Poznak, Bast, Hayes Tags: Epidemiology, Diagnosis & Staging, Chemotherapy, Combined Modality, Hormonal Therapy, ASCO Guidelines, Cancer Biomarkers ASCO SPECIAL ARTICLE Source Type: research

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma [UNDERSTANDING THE PATHWAY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Smits, Sentman Tags: Understanding the Pathway Source Type: research

Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study [Epidemiology]
Purpose Cardiovascular diseases (CVDs), including ischemic heart disease, stroke, and heart failure, are well-established late effects of therapy in survivors of childhood and young adult (
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Armenian, Xu, Ky, Sun, Farol, Pal, Douglas, Bhatia, Chao Tags: Population and observational studies (SEER, WHI observational, etc.) Epidemiology Source Type: research

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease [Hematologic Malignancy]
Conclusion Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT. The findings point toward a future when antigen-specific T-cell therapies will play a central role in alloHSCT. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Brudno, Somerville, Shi, Rose, Halverson, Fowler, Gea-Banacloche, Pavletic, Hickstein, Lu, Feldman, Iwamoto, Kurlander, Maric, Goy, Hansen, Wilder, Blacklock-Schuver, Hakim, Rosenberg, Gress, Kochenderfer Tags: Leukemia, Lymphoma, Biologic Therapy, Biological Therapy, Immunology/Immunobiology Hematologic Malignancy Source Type: research

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study [Hematologic Malignancy]
Conclusion In this phase I study of relapsed/refractory NHL, continuous infusion with CD19-targeted immunotherapy blinatumomab at various doses and schedules was feasible, with an MTD of 60 μg/m2/day. Single-agent blinatumomab showed antilymphoma activity. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Goebeler, Knop, Viardot, Kufer, Topp, Einsele, Noppeney, Hess, Kallert, Mackensen, Rupertus, Kanz, Libicher, Nagorsen, Zugmaier, Klinger, Wolf, Dorsch, Quednau, Schmidt, Scheele, Baeuerle, Leo, Bargou Tags: Clinical Trials, Phase I and Clinical Pharmacology, Translational Oncology, Hematologic Hematologic Malignancy Source Type: research

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction [Clinical Trials]
Conclusion Monthly infusions of NEOD001 were safe and well tolerated. Recommended future dosing was 24 mg/kg. Organ response rates compared favorably with those reported previously for chemotherapy. A phase II expansion is ongoing. A global phase III study (NCT02312206) has been initiated. Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Gertz, Landau, Comenzo, Seldin, Weiss, Zonder, Merlini, Schonland, Walling, Kinney, Koller, Schenk, Guthrie, Liedtke Tags: Phase I and Clinical Pharmacology Clinical Trials Source Type: research

Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer [Gynecologic Cancer]
We examined the use of minimally invasive surgery and the association between the route of the procedure and long-term survival. Methods We used the SEER-Medicare database to identify women with stage I-III uterine cancer who underwent hysterectomy from 2006 to 2011. Patients who underwent abdominal hysterectomy were compared with those who had minimally invasive hysterectomy (laparoscopic and robot-assisted). Perioperative morbidity, use of adjuvant therapy, and long-term survival were examined after propensity score balancing. Results We identified 6,304 patients, including 4,139 (65.7%) who underwent abdominal hystere...
Source: Journal of Clinical Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Wright, Burke, Tergas, Hou, Huang, Hu, Hillyer, Ananth, Neugut, Hershman Tags: Surgery Gynecologic Cancer Source Type: research